Vichy Laboratories launches new products designed to address signs of hormonal aging
NEW YORK — Vichy Laboratories, in conjunction with the kickoff for National Women’s Health Week, today announced the launch of new additions of skin care products for 50-something women designed to address the signs of hormonal aging.
Realizing the skin changes women go through during hormonal aging are extremely complex and intense, Vichy Laboratoires developed the Neovadiol collection, a line boasting luxurious formulas specially designed to address all signs of hormonal aging, in consultation with experts, such as dermatologists, obstetricians, gynecologists and psychologists, the company stated. And now the Neovadiol line has new products to help women combat wrinkles and other signs of hormonal aging.
New products in the Neovadiol line include new Neovadiol Gf Eye & Lip Contours and Neovadiol Lumiere BB Cream. These products complete the Neovadiol range, which already includes Neovadiol Gf Day and Night Cream ($55.00, 50ml), specially formulated to address the areas most affected by hormonal aging: the jawline, neck and cheeks.
New Neovadiol Gf Eye & Lip Contours ($47.00 for 15ml) is a new formula specially designed to address the fragile skin around both the eyes and lips. Scientists at Vichy discovered the delicate skin around the eyes and lips ages similarly due to hormonal changes and needs to be treated in a similar manner. Creases around these areas are visibly smoother, and skin is visibly plumped and tightened. The innovative cooling applicator adapts itself precisely to the contours around the eyes and lips to facilitate maximum absorption, while producing a soothing and refreshing sensation.
New Neovadiol Lumiere BB Cream ($42.00, 40ml) is a BB cream specially designed for the woman going through hormonal aging. It illuminates and visibly resculpts skin in one step with Vichy’s most advanced anti-aging technology. The pigmented cream, formulated with mother of pearl and other mineral pigments, benefits skin in six ways: densifies, resculpts, smoothes, nourishes, evens and illuminates skin. Lumiere is available in one universal shade that enhances any complexion.
During hormonal changes, the process of skin aging is accelerated. Dr. Rebecca Brightman, OBGYN: MD, FACOG, Vichy’s Expert on Women’s Health, explains, "Hormonal alterations can affect almost every organ system in the body — and that includes skin. There is a loss of subcutaneous fat and a decrease in skin collagen production, and as a result, skin loses its elasticity, causing fine lines, wrinkles and a sagging jawline."
New Vichy Neovadiol Gf Eye & Lip Contours and Lumiere BB Cream, along with the existing Neovadiol collection, is available nationwide at select Walgreens, CVS/pharmacy, Duane Reade and ULTA stores.
National Women’s Health Week is a week-long health observance coordinated by the U.S. Department of Health and Human Services in an effort to promote the importance of women’s health, empowering women to make their health a priority.
Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.
Inergetics launches line of supplements under Martha Stewart license
NEWARK, N.J. — Inergetics on Monday announced its partnership with Martha Stewart Living Omnimedia to create Martha Stewart Naturals, a line of six supplements that will launch this fall.
“We believe Martha Stewart embodies healthy living and well-being, putting that same philosophy in everything she does," stated Mike James, CEO Inergetics.
“I envisioned nutritious whole food-based supplements for women who live their lives the way I do, healthily and with passion,” Stewart said. “I have confidence that consumers will recognize the high quality and nutritional value these formulas deliver and that they will become as excited about them as I am.”
Stewart recently published "Living the Good Long Life: A Practical Guide to Caring for Yourself and Others" and furthers her commitment to living well with this new high-quality, affordably priced line of women’s supplements, the company stated.
FDA ruling on opioid painkiller deals blow to Endo
SILVER SPRING, Md. — A ruling by the Food and Drug Administration means that generic versions of an opioid painkiller made by Endo Pharmaceuticals can stay on the market, drawing criticism from the drug maker.
The FDA responded to a petition filed by Endo, a subsidiary of Endo Health Solutions, saying that an earlier version of the drug Opana ER (oxymorphone hydrochloride) was not withdrawn from the market due to reasons of safety and effectiveness because, unlike the newer version, it did not include abuse-deterrent features. The agency said that while the newer version of Opana ER can resist crushing better than the older version, it is still susceptible to abuse by cutting, grinding or chewing, and various methods would still allow its abuse through injection or snorting.
In December 2012, the U.S. District Court for the District of Columbia dismissed a case that Endo filed against the FDA, alleging that the agency had failed to fulfill an obligation to determine whether the original version of Opana ER was withdrawn for safety reasons, clearing the way for Impax Labs’ January 2013 launch of the generic.
The abuse-deterrent version of the drug was launched in early 2012, and in February, when Endo announced its fourth quarter 2012 earnings, the company said the new version had reduced the abuse rate by 59%.
Malvern, Pa.-based Endo said it was "extremely disappointed" with the decision. The company said the launch of generic versions of Opana ER would reduce the branded version of the drug’s sales by up to $120 million this year. The drug had sales of $299.3 million in 2012, down 22% from 2011’s $384.3 million, according to Endo.
"With the approval and expected launch of additional non-abuse deterrent generic versions of Opana ER, we will carefully assess Endo’s position in the competitive landscape and explore all options, including those intended to mitigate the effect of this decision," Endo president and CEO Rajiv De Silva said. "Endo remains committed to patient safety, including appropriate use of our products, as a top priority."
Meanwhile, the FDA reached a different conclusion with regard to generic versions of another commonly abused opioid painkiller, Purdue Pharma’s OxyContin (oxycodone). In April, the agency said it would not approve any generic version of OxyContin that did not include the abuse-deterrent features of the branded version.